Ms Heather L Frederick, PT | |
1525 Chapin Rd, Chapin, SC 29036-0337 | |
(803) 345-3811 | |
(803) 345-3018 |
Full Name | Ms Heather L Frederick |
---|---|
Gender | Female |
Speciality | Physical Medicine & Rehabilitation |
Location | 1525 Chapin Rd, Chapin, South Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1225177520 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | 4075 (South Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ms Heather L Frederick, PT Po Box 337, Chapin, SC 29036-0337 Ph: (803) 345-3811 | Ms Heather L Frederick, PT 1525 Chapin Rd, Chapin, SC 29036-0337 Ph: (803) 345-3811 |
News Archive
Using a yeast model of Alzheimer's disease (AD), Whitehead Institute researchers have identified a drug that reduces levels of the toxic protein fragment amyloid-β (Aβ) and prevents at least some of the cellular damage caused when Aβ accumulates in the brains of AD patients.
North America's only authorized facility for injecting illegal drugs has helped cut drug overdose deaths significantly in the Vancouver community where it is located and "should be used as a model in other cities," according to a study published on Monday in the Lancet, Reuters reports (Dowd, 4/18).
A recent study examined the ability of SARS-CoV-2 to impact DNA damage response and telomere stability in Vero E6 cells.
A team of Cornell University scientists from the College of Veterinary Medicine, Weill Cornell Medical College and the College of Agriculture and Life Sciences have discovered that a novel group of E. coli bacteria, containing genes similar to those described in uropathogenic and avian pathogenic E. coli and enteropathogenic bacteria such as salmonella, cholera, bubonic plague, is associated with intestinal inflammation in patients with Crohn's disease in their research paper published July 12 by the ISME Journal: Multidisciplinary Journal of Microbial Ecology.
Pulmonx, an emerging leader in interventional pulmonology, announced today that it has concluded an agreement for a new round of equity financing from an investment syndicate led by two new investors. The company also announced that it plans to use this capital to support the international commercial launch of its Zephyr® Endobronchial Valve (EBV), and its recently approved Chartis® Pulmonary Assessment System. Both products are CE marked and cleared for sale in Europe and other major international markets.
› Verified 4 days ago